# Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

> **NCT03441789** · PHASE4 · COMPLETED · sponsor: **L.H. Kircik, M.D.** · enrollment: 28 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Enstilar
- **DRUG:** Vehicle
- **DRUG:** Otezla

## Key facts

- **NCT ID:** NCT03441789
- **Lead sponsor:** L.H. Kircik, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2018-10-01
- **Final completion:** 2018-10-22
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03441789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03441789, "Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03441789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*